¼¼°èÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, Áö¿ªº° Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® º¸°í¼­ - Á¦°øº°, Àü°³º°, ±â¾÷ ±Ô¸ðº°, Çüź°, ±â´Éº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°
Pharmacovigilance and Drug Safety Software Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Offering, Deployment, Enterprise Size, Form, Functionality, End User, and Geography
»óǰÄÚµå : 1591394
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 388 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,450 £Ü 6,314,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 6,450 £Ü 9,153,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,450 £Ü 11,991,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 2¾ï 1,439¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2031³â¿¡´Â 3¾ï 5,931¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2023³âºÎÅÍ 2031³â±îÁö CAGRÀº 6.7% ±â·ÏÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç(APAC), Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA), Áß³²¹ÌÀÇ ÁÖ¿ä 5°³ Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù. 2023³â ½ÃÀå ±Ô¸ð´Â ºÏ¹Ì°¡ ¾ÐµµÀûÀ¸·Î Å©°í, À̾î À¯·´, ¾Æ½Ã¾Æ ÅÂÆò¾ç ¼øÀ̾ú½À´Ï´Ù. ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ºÏ¹Ì´Â ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾îÀÇ ¹ßÀü¿¡ Áö¼ÓÀûÀ¸·Î ³ë·ÂÇϰí ÀÖ´Â IQVIA Oracle ÄÚÆÛ·¹À̼ǰú °°Àº ´Ù¾çÇÑ ½ÃÀå ±â¾÷ÀÇ Á¸Àç·Î ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå¿¡¼­ ³î¶ó¿î ¼ºÀåÀ» º¸À̰í ÀÖ½À´Ï´Ù. 2024³â 7¿ù ¿À¶óŬ ÄÚÆÛ·¹À̼ÇÀº AI ±â¹Ý ¿À¶óŬ ¾Æ±¸½º Ç÷§ÆûÀ» Safety One Intake ¼Ö·ç¼ÇÀ¸·Î ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ¼Ö·ç¼ÇÀº »ý¸í °úÇРȸ»ç°¡ È®ÀåÇÏ´Â ±ÔÁ¦ ¿ä±¸ »çÇ×À» ÃæÁ·Çϰí Áõ°¡ÇÏ´Â À¯ÇØ »ç·Ê¸¦ ¿ÏÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ »õ·Î¿î ¾à¹°°¨½Ã Ç÷§ÆûÀº »ý»ê¼º Çâ»ó, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã °³¼±, º¸°í °­È­¸¦ ¸ñÀûÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ Áö¿ªÀÇ ½ÃÀå ±â¾÷¿¡ ÀÇÇÑ ÀÌ·¯ÇÑ Á¦Ç° Çõ½ÅÀº ÀÌ Áö¿ª¿¡¼­ÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº Àεµ, Áß±¹, ÀϺ», Çѱ¹, È£ÁÖ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¼ºÀå °æÁ¦±ÇÀ¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ¾Æ½Ã¾Æ ÅÂÆò¾ç Áö¿ª¿¡¼­´Â ÇコÄÉ¾î ºÐ¾ßÀÇ µðÁöÅÐÈ­°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª Á¤ºÎ´Â °Ç°­ °ü¸® ½Ã½ºÅÛÀ» °­È­ÇÏ°í µðÁöÅÐÈ­Çϱâ À§ÇØ ´Ù¾çÇÑ ³ë·ÂÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Áß±¹ °ø¹«¿ø ÀÇ·áºñ´Â 2023³â 3 185¾ï ´Þ·¯¿¡ À̸£·¶½À´Ï´Ù. Àεµ ºê·£µå ÀÚ±Ý Àç´Ü¿¡ µû¸£¸é ÀεµÀÇ °Ç°­ °ü¸® »ê¾÷Àº 2023³â 3,720¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç °ø°ø ºÎ¹®°ú ¹Î°£ ºÎ¹® ¸ðµÎ°¡ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡ Àüü¿¡¼­ ÀÌ·¯ÇÑ ÀÇ·á ÁöÃâ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ¼ºÀåÀ» À§ÇÑ ´ë±Ô¸ð ¼ö¿ä¸¦ »ý»êÇϰí ÀÖ½À´Ï´Ù.

±â¾÷ ±Ô¸ð¿¡ µû¶ó ¼¼°èÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº Áß¼Ò±â¾÷°ú ´ë±â¾÷À¸·Î 2ºÐÇÒ µË´Ï´Ù. ´ë±â¾÷ÀÇ ¾à¹°°¨½Ã ¼ÒÇÁÆ®¿þ¾î ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó 2023³â¿¡´Â ´ë±â¾÷ ºÎ¹®ÀÌ ±â¾÷ ±Ô¸ðº° ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¼¼°è¿¡ »ç¾÷À» Àü°³ÇÏ´Â ´ë±â¾÷Àº ¿©·¯ Áö¿ªÀÇ ¾à¹°°¨½Ã °¡À̵å¶óÀÎÀ» ÁؼöÇØ¾ß ÇÕ´Ï´Ù. ¾à¹°°¨½Ã ¼ÒÇÁÆ®¿þ¾î´Â ¼¼°èÀûÀÎ ¾ÈÀü¼º µ¥ÀÌÅÍÀÇ ÅëÇÕ°ú Ç¥ÁØÈ­¸¦ Áö¿øÇØ À̵é Á¶Á÷ÀÌ ¿©·¯ Áö¿ª¿¡¼­ ÀǾàǰÀÇ ¾ÈÀü¼ºÀ» ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ´ë±Ô¸ð Á¶Á÷¿¡¼­´Â ÀÓ»ó½ÃÇè Áß ¹× ½ÃÆÇ ÈÄ ¸ðµÎ ´ë·®ÀÇ À¯ÇØ »ç°Ç µ¥ÀÌÅ͸¦ ¹Þ½À´Ï´Ù. ¾à¹°°¨½Ã ¼ÒÇÁÆ®¿þ¾î´Â ÀÌ·¯ÇÑ Á¶Á÷ÀÌ Áõ°¡ÇÏ´Â µ¥ÀÌÅÍ ¾çÀ» È¿À²ÀûÀ¸·Î °ü¸®ÇÏ°í ºÐ¼®ÇÏ¿© ÄÄÇöóÀ̾𽺠À§¹Ý ¹× ¾ÈÀü ½ÅÈ£¸¦ ³õÄ¥ °¡´É¼ºÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¾à¹°°¨½Ã ¼ÒÇÁÆ®¿þ¾î´Â ±â¹Ð¼ºÀÌ ³ôÀº ȯÀÚ µ¥ÀÌÅ͸¦ ó¸®Çϱâ À§ÇØ ´ë±â¾÷Àº À¯·´ÀÇ ÀÏ¹Ý µ¥ÀÌÅÍ º¸È£ ±ÔÄ¢(GDPR-EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤)°ú °°Àº µ¥ÀÌÅÍ º¸È£ ±ÔÁ¤¿¡ ´ëÇÑ Áؼö¸¦ º¸ÀåÇϱâ À§ÇØ °­·ÂÇÑ µ¥ÀÌÅÍ º¸¾È ¹× °³ÀÎ Á¤º¸ º¸È£ ±â´ÉÀ» °®Ãá ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀ» ä¿ëÇϰí ÀÖ½À´Ï´Ù.

ArisEurope; ICON plc; Syneos Health; Accenture; IQVIA; Genpact; Cognizant; Paraxel International Corporation; Laboratory Corporation of America Holdings; Max Application; Clinevo Technologies; Qinecsa Solutions; AB Cube; ¹× Veeva SystemsÀº ÀÌ ½ÃÀå Á¶»ç¿¡¼­ ºÐ¼®µÇ°í ÀÖ´Â ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ±Ô¸ð´Â 1Â÷Á¤º¸ ¹× 2Â÷Á¤º¸ ¸ðµÎ¸¦ ÀÌ¿ëÇÏ¿© »êÃâµÇ°í ÀÖ½À´Ï´Ù. ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾îÀÇ ½ÃÀå ±Ô¸ð¿¡ °ü·ÃµÇ´Â Á¤¼ºÀû ¹× Á¤·®Àû Á¤º¸¸¦ ¾ò±â À§ÇØ »ç³»¿ÜÀÇ Ãâó¸¦ ÀÌ¿ëÇÏ¿© öÀúÇÑ 2Â÷ Á¶»ç¸¦ ½Ç½ÃÇß½À´Ï´Ù. ÀÌ ÇÁ·Î¼¼½º´Â ¸ðµç ½ÃÀå ºÎ¹®¿¡ °üÇÑ ½ÃÀåÀÇ °³¿ä¿Í ¿¹ÃøÀ» ¾ò´Â µ¥µµ µµ¿òÀÌ µË´Ï´Ù. ¶Ç, µ¥ÀÌÅ͸¦ °ËÁõÇÏ°í ºÐ¼®Àû ÀλçÀÌÆ®¸¦ ¾ò±â À§ÇØ ¾÷°è °ü°èÀڵ鿡°Ô 1Â÷ ÀÎÅͺ並 ½Ç½ÃÇß½À´Ï´Ù. ÀÌ ÇÁ·Î¼¼½º¿¡´Â ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀ» Àü¹®À¸·Î ÇÏ´Â ºÎ»çÀå, ½ÃÀå °³¹ß ¸Å´ÏÀú, ½ÃÀå ÀÎÅÚ¸®Àü½º ¸Å´ÏÀú, ±¹³» ¿µ¾÷ ¸Å´ÏÀú µîÀÇ ¾÷°è Àü¹®°¡¿Í Æò°¡ Àü¹®°¡, ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®, Ű¿ÀÇǴϾ𠸮´õ µî ¿ÜºÎ ÄÁ¼³ÅÏÆ®°¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå »óȲ

Á¦5Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå-ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

Á¦7Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : Á¦°øº°

Á¦8Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : Àü°³º°

Á¦9Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : ±â¾÷ ±Ô¸ðº°

Á¦10Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : Çüź°

Á¦11Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : ±â´Éº°

Á¦12Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦13Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå ¾÷°è Á¤¼¼

Á¦16Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦17Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The pharmacovigilance and drug safety software market size was valued at US$ 214.39 million in 2023 and is expected to reach US$ 359.31 million by 2031; it is estimated to record a CAGR of 6.7% from 2023 to 2031.

The pharmacovigilance and drug safety software market is segmented into five major regions-North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South & Central America. North America dominated the market in 2023, followed by Europe and Asia Pacific, respectively. The pharmacovigilance and drug safety software market in North America is segmented into the US, Canada, and Mexico. North America is witnessing tremendous growth in the pharmacovigilance and drug safety software market, owing to the presence of various market players such as IQVIA Oracle Corporation, who are continuously working on the advancement of pharmacovigilance and drug safety software. In July 2024, Oracle Corporation launched an AI-based Oracle Argus platform as a Safety One Intake solution. This solution helps life science organizations to meet growing regulatory requirements and to mitigate the rising volume of adverse event cases. This new pharmacovigilance platform aimed to increase productivity, improve data privacy, and enhance reporting. Thus, such product innovations by the market players in the region are fueling the growth of the pharmacovigilance and drug safety software market in the area.

Asia Pacific consists of various growing economies such as India, China, Japan, South Korea, Australia, and Rest of Asia Pacific. Asia Pacific is witnessing growing digitization in its healthcare sector. The governments of various countries in the region are taking different initiatives to enhance and digitize the healthcare system. For instance, China's healthcare expenditure of public financial officials reached US$ 318.5 billion in 2023. According to the India Brand Equity Foundation, the Indian Healthcare industry was valued at US$ 372 billion in 2023, driven by both the public and private sectors. Such rising healthcare expenditure across the Asia Pacific countries has created massive demand for the pharmacovigilance and drug safety software market growth during the forecast period.

Based on enterprise size, the global pharmacovigilance and drug safety software market is bifurcated into SMEs and large enterprises. The large enterprises segment dominated the market for enterprise size in 2023 owing to increasing investment by large companies in pharmacovigilance software. Large organizations with global operations must adhere to the pharmacovigilance guidelines of multiple regions. Pharmacovigilance software helps consolidate and standardize global safety data, ensuring that these organizations can monitor drug safety in real time across multiple geographies. Large organizations receive a high volume of adverse event data, both during clinical trials and post-marketing. Pharmacovigilance software helps these organizations manage and analyze the increasing data volume effectively, reducing the chances of noncompliance or missed safety signals. As pharmacovigilance software processes sensitive patient data, large organizations are adopting software solutions with robust data security and privacy features to ensure compliance with data protection regulations such as the General Data Protection Regulation (GDPR) in Europe.

ArisEurope; ICON plc; Syneos Health; Accenture; IQVIA; Genpact; Cognizant; Paraxel International Corporation; Laboratory Corporation of America Holdings; Max Application; Clinevo Technologies; Qinecsa Solutions; AB Cube; and Veeva Systems are among the key pharmacovigilance and drug safety software market players that are profiled in this market study.

The overall pharmacovigilance and drug safety software market size has been derived using both primary and secondary sources. Exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the pharmacovigilance and drug safety software market size. The process also helps obtain an overview and forecast of the market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and gain analytical insights. This process includes industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the pharmacovigilance and drug safety software market.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Pharmacovigilance and Drug Safety Software Market Landscape

5. Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics

6. Pharmacovigilance and Drug Safety Software Market - Global Market Analysis

7. Pharmacovigilance and Drug Safety Software Market Analysis - by Offering

8. Pharmacovigilance and Drug Safety Software Market Analysis - by Deployment

9. Pharmacovigilance and Drug Safety Software Market Analysis - by Enterprise Size

10. Pharmacovigilance and Drug Safety Software Market Analysis - by Form

11. Pharmacovigilance and Drug Safety Software Market Analysis - by Functionality

12. Pharmacovigilance and Drug Safety Software Market Analysis - by End User

13. Pharmacovigilance and Drug Safety Software Market - Geographical Analysis

14. Competitive Landscape

15. Industry Landscape

16. Company Profiles

17. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â